Diagnostic kit for the detection of human papilloma virus (HPV) integration status (iHPV kit).
Cervical cancer is the seventh most common malignancy with mortality rate of 6.8 per 100,000 people. It is caused by the presence of aggressive forms of HPV (human papilloma virus). More than 2.6 billion woman are at the risk of the cancer and about 500.000 cases are annually detected worldwide. The technology allows the sensitive detection of the most abundant high-risk HPV presence in a sample with additional information about integration status, where episomal (not-integrated) forms of the HPV are less pathogenic than the integrated HPV forms. It expands the information and helps to provide the patients effective treatment. The procedure is simple to perform, rapid and reliable.
The principle of the technology is based on a quantitative fluorescent detection of amplification of HPV genes E2, E6 using the polymerase chain reaction (PCR) in real time using specific TaqMan probes. The technology detects 3 genes (HPV E2, E6, and human GAPDH) in one PCR reaction and contains 3 different fluorescent dyes compatible with mainstream real-time termocyclers. The GAPDH detection serves as an internal control of amplification and/or DNA presence in the PCR reaction. The technology is currently able to detect these high-risk genotypes of HPV: 16, 18, 31, 56. Could be adapted for further genotypes detection.
Prototype of a diagnostic kit, stability tests, performance tests, primer design, optimized standard operation protocol, documentation for manufacturing, related know how.
The main benefit of the technology over existing diagnostic kit features resolution form of the virus (a form of free - episomal and integrated form). Integration of HPV has been associated with disease (cancer) progression. The technology is capable of absolute quantification of HPV load in the sample. Able to detect only 4 copies in HPV genome in analyzed sample per PCR reaction.
Subject to confidentiality, protected know-how
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc
More information is available upon signing a CDA/NDA. Please contact IMTM´s director (firstname.lastname@example.org) or the technology transfer office (email@example.com).